resveratrol has been researched along with Fatty Liver, Nonalcoholic in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.19) | 29.6817 |
| 2010's | 49 (58.33) | 24.3611 |
| 2020's | 34 (40.48) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, L; Liu, L; Quan, S; Shen, L; Shi, X; Wang, H; Wang, X; Wang, Z; Xie, L | 1 |
| Abiri, B; Guest, PC; Karimi, M; Vafa, M | 1 |
| Chen, XX; Hu, JN; Li, X; Wu, WF; Xu, XB; Xu, Y; Zhao, Q | 1 |
| An, X; Hu, L; Kong, L; Liu, L; Nan, Y; Wang, R; Zhang, S; Zhao, S | 1 |
| Li, B; Li, L; Wang, C; Xu, C; Ye, F; Yuan, W; Zhang, M | 1 |
| Abdollahi, S; Ali Sangouni, A; Mozaffari-Khosravi, H | 1 |
| Ezhilarasan, D; Lakshmi, T | 1 |
| Chen, J; Ge, A; Ge, J; Wang, S; Xu, H; Yang, K; Yuan, X; Zeng, L; Zhang, T | 1 |
| Bao, Z; Huang, Y; Mi, L; Tong, Y; Yu, X; Zhang, Z | 1 |
| Duttaroy, AK; Jena, AB; Kerry, RG; Patnaik, D | 1 |
| Bahreini, E; Barzin Tond, S; Fadaei, R; Fallah, S; Farahmandian, N; Karima, S; Koushki, M; Nourbakhsh, M; Rezaei, A; Yarahmadi, S | 1 |
| Elamir, AM; Elsayed, AM; Golam, RM; Ibrahim, NA; Merzeban, DH; Shamardl, HAMA | 1 |
| Feng, S; Han, H; Shi, M; Tang, J; Wang, L; Zhang, T | 1 |
| Deng, J; Hao, L; Hu, X; Li, S; Zhang, J | 1 |
| Chang, D; Chen, T; He, Y; Huang, M; Huang, Q; Li, S; Lin, S; Lin, Y; Liu, Y; Lu, Y; Song, J; Sun, Y; Wang, C; Wang, H; Xu, W; Zheng, Y; Zhou, X | 1 |
| Babaei Khorzoughi, R; Hosseini, H; Izadi, P; Koushki, M; Meshkani, R; Namvarjah, F; Shabani, M; Teimouri, M | 1 |
| Aragonès, G; Ardid-Ruiz, A; Arola, L; Del Rio, D; Ibars, M; Mena, P; Muguerza, B; Suárez, M | 1 |
| Aasbrenn, M; Abd El-Aty, AM; Abdu, A; Abraha, HB; Achour, A; Acquaroni, M; Addeo, P; Agback, P; Agback, T; Al-Alwan, M; Al-Mazrou, A; Al-Mohanna, F; Aliste, M; Almquist, J; Andel, J; Ando, M; Angelov, A; Annuar, MSM; Antwi, K; Arroliga, AC; Arruda, SLM; Asch, SM; Averous, G; Ayaz, S; Ayer, GB; Bachellier, P; Ball, S; Banijamali, AR; Barden, TC; Bartoncini, S; Bedanie, G; Bellò, M; Benić, F; Berhe, GG; Bertiger, G; Beumer, JH; Bhandari, B; Bond, DS; Boules, M; Braüner Christensen, J; Brown-Johnson, C; Burgstaller, S; Cao, L; Capasso, C; Carlevato, R; Carvalho, AE; Ceci, F; Chagas, ATA; Chavan, SG; Chen, AP; Chen, HC; Chen, J; Chen, Q; Chen, Y; Chen, YF; Christ, ER; Chu, CW; Covey, JM; Coyne, GO'; Cristea, MC; Currie, MG; Dahdal, DN; Dai, L; Dang, Z; de Abreu, NL; de Carvalho, KMB; de la Plaza Llamas, R; Deandreis, D; Del Prete, S; Dennis, JA; Deur, J; Díaz Candelas, DA; Divyapriya, G; Djanani, A; Dodig, D; Doki, Y; Doroshow, JH; Dos Santos, RC; Durairaj, N; Dutra, ES; Eguchi, H; Eisterer, W; Ekmann, A; Elakkad, A; Evans, WE; Fan, W; Fang, Z; Faria, HP; Farris, SG; Fenoll, J; Fernandez-Botran, R; Flores, P; Fujita, J; Gan, L; Gandara, DR; Gao, X; Garcia, AA; Garrido, I; Gebru, HA; Gerger, A; Germano, P; Ghamande, S; Ghebeh, H; Giver Jensen, T; Go, A; Goichot, B; Goldwater, M; Gontero, P; Greil, R; Gruenberger, B; Guarneri, A; Guo, Y; Gupta, S; Haxholdt Lunn, T; Hayek, AJ; He, ML; Hellín, P; Hepprich, M; Hernández de Rodas, E; Hill, A; Hndeya, AG; Holdsworth, LM; Hookey, L; Howie, W; Hu, G; Huang, JD; Huang, SY; Hubmann, E; Hwang, SY; Imamura, H; Imperiale, A; Jiang, JQ; Jimenez, JL; Jin, F; Jin, H; Johnson, KL; Joseph, A; Juwara, L; Kalapothakis, E; Karami, H; Karayağiz Muslu, G; Kawabata, R; Kerwin, J; Khan, I; Khin, S; Kidanemariam, HG; Kinders, RJ; Klepov, VV; Koehler, S; Korger, M; Kovačić, S; Koyappayil, A; Kroll, MH; Kuban, J; Kummar, S; Kung, HF; Kurokawa, Y; Laengle, F; Lan, J; Leal, HG; Lee, MH; Lemos, KGE; Li, B; Li, G; Li, H; Li, X; Li, Y; Li, Z; Liebl, W; Lillaz, B; Lin, F; Lin, L; Lin, MCM; Lin, Y; Lin, YP; Lipton, RB; Liu, J; Liu, W; Liu, Z; Lu, J; Lu, LY; Lu, YJ; Ludwig, S; Luo, Y; Ma, L; Ma, W; Machado-Coelho, GLL; Mahmoodi, B; Mahoney, M; Mahvash, A; Mansour, FA; Mao, X; Marinho, CC; Masferrer, JL; Matana Kaštelan, Z; Melendez-Araújo, MS; Méndez-Chacón, E; Miletić, D; Miller, B; Miller, E; Miller, SB; Mo, L; Moazzen, M; Mohammadniaei, M; Montaz-Rosset, MS; Mousavi Khaneghah, A; Mühlethaler, K; Mukhopadhyay, S; Mulugeta, A; Nambi, IM; Navarro, S; Nazmara, S; Neumann, HJ; Newman, EM; Nguyen, HTT; Nicolato, AJPG; Nicolotti, DG; Nieva, JJ; Nilvebrant, J; Nocentini, A; Nugent, K; Nunez-Rodriguez, DL; Nygren, PÅ; Oberli, A; Oderda, M; Odisio, B; Oehler, L; Otludil, B; Overman, M; Özdemir, M; Pace, KA; Palm, H; Parchment, RE; Parise, R; Passera, R; Pavlovic, J; Pecherstorfer, M; Peng, Z; Pérez Coll, C; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Piekarz, RL; Pilati, E; Pimentel, JDSM; Posch, F; Prager, G; Pressel, E; Profy, AT; Qi, P; Qi, Y; Qiu, C; Rajasekhar, B; Ramia, JM; Raynor, HA; Reis, VW; Reubi, JC; Ricardi, U; Riedl, JM; Romano, F; Rong, X; Rubinstein, L; Rumboldt, Z; Sabir, S; Safaeinili, N; Sala, BM; Sandoval Castillo, L; Sau, M; Sbhatu, DB; Schulte, T; Scott, V; Shan, H; Shao, Y; Shariatifar, N; Shaw, JG; She, Y; Shen, B; Shernyukov, A; Sheth, RA; Shi, B; Shi, R; Shum, KT; Silva, JC; Singh, A; Sinha, N; Sirajudeen, AAO; Slaven, J; Sliwa, T; Somme, F; Song, S; Steinberg, SM; Subramaniam, R; Suetta, C; Sui, Y; Sun, B; Sun, C; Sun, H; Sun, Y; Supuran, CT; Surger, M; Svartz, G; Takahashi, T; Takeno, A; Tam, AL; Tang, Z; Tanner, JA; Tannich, E; Taye, MG; Tekle, HT; Thomas, GJ; Tian, Y; Tobin, JV; Todd Milne, G; Tong, X; Une, C; Vela, N; Venkateshwaran, U; Villagrán de Tercero, CI; Wakefield, JD; Wampfler, R; Wan, M; Wang, C; Wang, J; Wang, L; Wang, S; Waser, B; Watt, RM; Wei, B; Wei, L; Weldemichael, MY; Wellmann, IA; Wen, A; Wild, D; Wilthoner, K; Winder, T; Wing, RR; Winget, M; Wöll, E; Wong, KL; Wong, KT; Wu, D; Wu, Q; Wu, Y; Xiang, T; Xiang, Z; Xu, F; Xu, L; Yamasaki, M; Yamashita, K; Yan, H; Yan, Y; Yang, C; Yang, H; Yang, J; Yang, N; Yang, Y; Yau, P; Yu, M; Yuan, Q; Zhan, S; Zhang, B; Zhang, H; Zhang, J; Zhang, N; Zhang, Y; Zhao, X; Zheng, BJ; Zheng, H; Zheng, W; Zhou, H; Zhou, X; Zhu, S; Zimmer, DP; Zionts, D; Zitella, A; Zlott, J; Zolfaghari, K; Zuo, D; Zur Loye, HC; Žuža, I | 1 |
| Hou, MC; Hsieh, YC; Hsu, CF; Huang, CC; Huang, SF; Huang, YH; Lee, TY; Li, TH; Lin, HC; Lin, MW; Liu, CW; Tsai, CY; Tsai, HC; Tsai, YL; Yang, YY | 1 |
| Chen, F; Hu, X; Ke, W; Li, D; Wang, J; Wang, P | 1 |
| Che, Y; Li, Y; Shi, X; Shi, Y; Si, R; Zhang, Y; Zhong, X | 1 |
| Chen, Y; Ji, S; Jia, P; Shen, M; Wang, T; Zhang, H; Zhang, Y | 1 |
| Bai, L; Gong, P; Guan, M; Liang, X; Liu, T; Lv, Y; Wang, J; Yi, H; Zhang, J; Zhang, L; Zhang, Z; Zhou, H; Zhou, X | 1 |
| Bally, L; Glisic, M; Kilchoer, B; Minder, B; Muka, T; Vils, A | 1 |
| Gutowska, I; Jakubczyk, K; Janda, K; Kałduńska, J; Skonieczna-Żydecka, K; Stachowska, E | 1 |
| Bezhuashvili, M; Gabruashvili, D; Kachlishvili, T; Ksovreli, M; Kulikova, N; Museridze, M; Zaalishvili, G | 1 |
| Aguirre, L; Gómez-Zorita, S; Milton-Laskibar, I; Portillo, MP; Rolo, AP | 1 |
| Wei, S; Yu, X | 1 |
| Askari, G; Ghavami, A; Mohammadi, H; Rafiee, S; Sadeghi, E; Safari, Z | 1 |
| Abenavoli, L; Boccuto, L; Corea, A; Dallio, M; Federico, A; Larussa, T; Luzza, F; Procopio, AC | 1 |
| El-Demerdash, E; Elsherbiny, DA; Gerges, SH; Wahdan, SA | 1 |
| Gamboa-Gómez, CI; Guerrero-Romero, F; Rodríguez-Ramírez, M; Sánchez-García, A; Simental-Mendía, LE; Simental-Mendía, M | 1 |
| Carrillo de Santa Pau, E; Fernández-Quintela, A; Gómez-Zorita, S; Marcos-Zambrano, LJ; Martínez, JA; Milton-Laskibar, I; Portillo, MP | 1 |
| Jayedi, A; Shab-Bidar, S; Zeraattalab-Motlagh, S | 1 |
| AboElnas, MM; Atta, AA; Elgebaly, A; Eltoomy, MF; Ibrahim, HH; Mesalam, HA; Othman, AA; Radwan, IA; Sayed, AA | 1 |
| Deng, KY; Guan, XH; Hu, L; Huang, CC; Qian, YS; Wang, LF; Wang, XN; Xiao, YF; Xin, HB | 1 |
| Di Giacomo, M; Ferramosca, A; Zara, V | 1 |
| Cygal, M; Czajkowska-Bania, K; Dudka, J; Gawrońska-Grzywacz, M; Gieroba, R; Herbet, M; Izdebska, M; Korga, A; Korolczuk, A; Piątkowska-Chmiel, I; Sysa, M | 1 |
| Bu, Y; Ding, S; Jiang, J; Zhang, G; Zhao, X | 1 |
| Bae, M; Lee, JY; Park, YK | 1 |
| Farzanegi, P; Hajighasem, A; Mazaheri, Z | 1 |
| Bombrich, M; Fritsche, A; Fritsche, L; Häring, HU; Heni, M; Kantartzis, K; Kunz, I; Lehn-Stefan, A; Machann, J; Peter, A; Schick, F; Schoop, R; Staiger, H; Stefan, N | 1 |
| Banach, M; Cicero, AFG; Fogacci, F | 1 |
| Bibby, BM; Grønbaek, H; Nellemann, B; Nielsen, S; Pedersen, SB; Poulsen, MK; Stødkilde-Jørgensen, H | 1 |
| Aguirre, L; Etxeberria, U; Martínez, JA; Milagro, FI; Milton-Laskibar, I; Portillo, MP | 1 |
| Huang, LT; Lai, YJ; Lin, IC; Lin, YJ; Sheen, JM; Tain, YL; Tiao, MM; Tsai, CC; Yu, HR | 1 |
| Bellentani, S; Cicero, AFG; Colletti, A | 1 |
| Jin, X; Koniaris, LG; Zhang, Z; Zimmers, TA | 1 |
| Liu, K; Mi, M; Qin, Y; Ye, X; Yi, L; Zeng, X; Zhang, Q; Zhou, R | 1 |
| Bao, J; Fu, X; Li, Y; Li, Z; Liu, S; Miao, L; Qiao, L; Xu, K; Zhang, X; Zhao, X; Zhou, Y | 1 |
| Cai, X; Chen, H; Liang, G; Liu, H; Pan, J; Shan, X; Wu, B; Xiao, Z; Zhang, W; Zhang, Y; Zhou, B | 1 |
| Cheng, K; Li, S; Song, Z; Wang, C; Wang, T; Zhang, H; Zhang, L | 1 |
| Badi, RM; Khaleel, EF; Mostafa, DG; Satti, HH | 1 |
| Chen, K; Gao, Y; Huang, Y; Lang, H; Mi, M; Ran, L; Yi, L; Zhang, Q; Zhang, Y | 1 |
| Chen, M; Hou, P; Huang, L; Hui, S; Mi, M; Ren, Q; Wang, X; Yi, L; Zhou, M | 1 |
| Bao, C; Jin, J; Li, D; Li, Y; Liu, M; Luo, J; Ren, F; Teng, W; Xiong, W; Yang, S; Zhang, C; Zhang, M; Zhao, L | 1 |
| Ho, CT; Lai, CS; Pan, MH; Tsai, ML | 1 |
| Chachay, VS; Coombes, JS; Cowin, GJ; Ferguson, M; Franklin, M; Hickman, IJ; Kirkpatrick, CM; Klein, K; Lee, P; Macdonald, GA; Martin, JH; O'Moore-Sullivan, TM; Prins, JB; Taylor, PJ; Thomas, GP; Whitehead, JP | 1 |
| Choi, YJ; Kim, DG; Kim, S; Lee, BH; Lee, KJ; Suh, HR; Yoon, Y | 1 |
| Aguirre, L; Bujanda, L; Hijona, E; Portillo, MP | 1 |
| Adibi, P; Faghihzadeh, F; Hekmatdoost, A; Rafiei, R | 1 |
| Chen, S; Gao, Y; Mi, M; Qin, Y; Ran, L; Shu, F; Wan, J; Wang, X; Yuan, L; Zhang, Q; Zhao, X | 1 |
| Musso, G | 1 |
| Aguirre, L; Arias, N; Macarulla, MT; Miranda, J; Portillo, MP | 1 |
| Chang, H; Chen, ML; Chen, SH; Gao, YX; Mi, MT; Ran, L; Wu, B; Wu, Y; Yi, L; Zhang, QY; Zhang, T; Zhang, Y; Zhou, X; Zhou, Y; Zhu, JD; Zou, D | 1 |
| Hu, YJ; Liu, WX; Pan, QR; Ren, YL; Wang, G; Xu, Y; Zheng, JS | 1 |
| Abdel-Latif, HA; Ali, MH; Messiha, BA | 1 |
| Adibi, P; Faghihzadeh, F; Hekmatdoost, A | 1 |
| Dolinsky, VW; Duhamel, T; McGavock, J; Robert, M; T' Jong, GW; Wicklow, B; Wittmeier, K | 1 |
| Christensen, LP; El-Houri, RB; Grønbaek, H; Haldrup, D; Heebøll, S; Hellberg, YE; Jessen, N; Pedersen, SB | 1 |
| Deng, Y; Ji, G; Jiang, Z; Li, X; Wang, Y | 1 |
| Gao, D; Gao, L; Hu, Y; Li, Z; Ma, X; Peng, J; Shan, W; Tian, X; Wang, G; Xu, W; Yao, J; Zeng, W; Zhang, N | 1 |
| Bønløkke Pedersen, S; Grønbæk, H; Hamilton-Dutoit, S; Heebøll, S; Jessen, N; Kjær Poulsen, M; Kreuzfeldt, M; Kristina Hellberg, Y; Møller, HJ; Stødkilde-Jørgensen, H; Thorsen, K | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nagashima, Y; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Abd El-Haleim, EA; Bahgat, AK; Saleh, S | 1 |
| Fang, J; He, P; Lei, J; Wang, C; Wang, W; Yuan, W; Zhang, C | 1 |
| Li, D; Ma, J; Tian, Y; Wang, K; Wang, W; Xu, J; Zhang, L | 1 |
| Chiba, T; Noji, K; Shimokado, K; Shinozaki, S; Suzuki, S; Umegaki, K | 1 |
| Ibdah, JA; Nassir, F | 1 |
| Berk, K; Chabowski, A; Charytoniuk, T; Drygalski, K; Konstantynowicz-Nowicka, K | 1 |
| He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY | 1 |
| Chen, Q; Li, J; Qiu, F; Wang, S; Wang, T; Yu, H; Zhang, Y | 1 |
| Clasen, BF; Hamilton-Dutoit, S; Jessen, N; Kjær, TN; Larsen, JØ; Paulsen, SK; Pedersen, SB; Poulsen, MM; Richelsen, B | 1 |
| Cui, W; Gao, D; Han, H; Hao, L; Sun, X; Xin, P; Yang, X; Ying, C | 1 |
22 review(s) available for resveratrol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Topics: Antioxidants; Humans; Liver; Liver Neoplasms; NF-kappa B; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Resveratrol; Silybin; Silymarin | 2022 |
Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Topics: Alanine Transaminase; Anthocyanins; Aspartate Aminotransferases; Catechin; Cholesterol, HDL; Cholesterol, LDL; Curcumin; Dietary Supplements; Genistein; Hesperidin; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Plant Extracts; Polyphenols; Resveratrol; Silymarin; Triglycerides | 2022 |
Efficacy of Dietary Supplements to Reduce Liver Fat.
Topics: Adipose Tissue; Adult; Carnitine; Catechin; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Limosilactobacillus reuteri; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol; Treatment Outcome | 2020 |
Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Antioxidants; Dietary Supplements; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol; Treatment Outcome | 2020 |
The influence of dietary conditions in the effects of resveratrol on hepatic steatosis.
Topics: Administration, Oral; Diet, High-Fat; Diet, Reducing; Humans; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Resveratrol | 2020 |
Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Topics: Dietary Supplements; Humans; Liver; Middle Aged; Non-alcoholic Fatty Liver Disease; Resveratrol | 2021 |
Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials.
Topics: Dietary Supplements; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Resveratrol; Triglycerides | 2021 |
Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Curcumin; Diet; Dietary Supplements; Disease Models, Animal; Humans; Mice; Non-alcoholic Fatty Liver Disease; Polyphenols; Resveratrol; Silymarin | 2021 |
Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Topics: Curcumin; Humans; Insulin Resistance; Liver; Liver Transplantation; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Plant Preparations; Resveratrol; Risk Factors | 2021 |
Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease.
Topics: Antioxidants; Biological Products; Humans; Liver; Non-alcoholic Fatty Liver Disease; Resveratrol | 2021 |
The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Insulin Resistance; Lipids; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol | 2021 |
Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Bias; Biomarkers; Blood Glucose; Cytokines; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol; Severity of Illness Index; Stilbenes | 2017 |
Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
Topics: Animals; Anthocyanins; Antioxidants; Carotenoids; Catechin; Coumestrol; Curcumin; Energy Metabolism; Fatty Liver; Glucosinolates; Humans; Imidoesters; Isothiocyanates; Lipogenesis; Mitochondria; Non-alcoholic Fatty Liver Disease; Nutritional Sciences; Oxidative Stress; Oximes; Polyphenols; Quercetin; Resveratrol; Stilbenes; Sulfoxides; Xanthophylls | 2017 |
Food components with antifibrotic activity and implications in prevention of liver disease.
Topics: Blueberry Plants; Coffee; Curcumin; Food; Hepatic Stellate Cells; Hepatocytes; Humans; Liver Cirrhosis; Macrophages; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol; Vitamins; Xanthophylls | 2018 |
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Topics: Antioxidants; Berberine; Curcumin; Dietary Supplements; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Observational Studies as Topic; Plant Extracts; Probiotics; Randomized Controlled Trials as Topic; Resveratrol; Salvia miltiorrhiza; Silymarin; Ubiquinone; Vitamin D; Vitamin E; Xanthophylls | 2018 |
Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.
Topics: Adipokines; Animals; Carotenoids; Curcumin; Fatty Acids, Omega-3; Fatty Liver; Flavonols; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Polyphenols; Resveratrol; Stilbenes | 2014 |
Effects of resveratrol and other polyphenols in hepatic steatosis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Humans; Hypolipidemic Agents; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Plants, Medicinal; Polyphenols; Quercetin; Resveratrol; Stilbenes; Treatment Outcome | 2014 |
Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
Topics: Cholesterol; Female; Humans; Lipoproteins; Male; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes | 2016 |
Sirtuins and nonalcoholic fatty liver disease.
Topics: Animals; Down-Regulation; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Non-alcoholic Fatty Liver Disease; Resveratrol; Sirtuins; Stilbenes | 2016 |
Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials.
Topics: Complementary Therapies; Hepatocytes; Humans; Insulin Resistance; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes | 2017 |
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases | 2016 |
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
Topics: Animals; Biological Products; Catechin; Curcumin; Fructose; Humans; Inflammation; Insulin Resistance; Lipogenesis; Mitochondria; Non-alcoholic Fatty Liver Disease; Resveratrol; Stilbenes | 2017 |
10 trial(s) available for resveratrol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Method; Humans; Iran; Non-alcoholic Fatty Liver Disease; Overweight; Resveratrol | 2022 |
Topics: 3-Hydroxybutyric Acid; Acetazolamide; Acrylates; Administration, Intravenous; Adolescent; Adult; Aerosols; Afghanistan; Aflatoxin M1; Agaricales; Aged; Aged, 80 and over; Agricultural Irrigation; Air Pollutants; alpha-L-Fucosidase; Amino Acid Sequence; Androgen Antagonists; Animals; Antibodies, Bacterial; Antigens, Bacterial; Antineoplastic Agents; Antioxidants; Apoptosis; Artifacts; Autophagy; B7-H1 Antigen; Bacterial Proteins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Bile; Bioelectric Energy Sources; Biosensing Techniques; Body Mass Index; Brain; Brazil; Breast Neoplasms; Bufo arenarum; Burkholderia; C-Reactive Protein; Cadmium; Carbon Compounds, Inorganic; Carbon-13 Magnetic Resonance Spectroscopy; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Carcinoma, Transitional Cell; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Count; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Characiformes; Child; China; Cities; Cobalt; Colonic Neoplasms; Copper Sulfate; Cross-Sectional Studies; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Deoxycytidine; Diagnosis, Differential; Digestive System; Dihydroxyphenylalanine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Barcoding, Taxonomic; DNA, Bacterial; Dose-Response Relationship, Drug; Down-Regulation; Edetic Acid; Electrochemical Techniques; Electrodes; Embolization, Therapeutic; Embryo, Nonmammalian; Environmental Monitoring; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Fatty Acids; Feces; Female; Follow-Up Studies; Food Contamination; Forkhead Box Protein M1; Fresh Water; Fungicides, Industrial; Gallium Isotopes; Gallium Radioisotopes; Gastrectomy; Gastric Bypass; Gastric Outlet Obstruction; Gastroplasty; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Bacterial; Genetic Markers; Genome, Bacterial; Genome, Mitochondrial; Glioma; Glycogen Synthase Kinase 3 beta; Goats; Gonads; Guatemala; Halomonadaceae; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hepacivirus; Histone-Lysine N-Methyltransferase; Hormones; Humans; Hydroxybutyrate Dehydrogenase; Hypersplenism; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Iran; Japan; Lactuca; Laparoscopy; Larva; Ligands; Liver Neoplasms; Lymphocyte Activation; Macrophages; Malaria; Male; Mercury; Metabolic Syndrome; Metals, Heavy; Mice; Middle Aged; Milk, Human; Mitochondria; Models, Molecular; Molecular Structure; Mothers; Multilocus Sequence Typing; Muscles; Mutation; Nanocomposites; Nanotubes, Carbon; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neuroimaging; Nitriles; Nitrogen Isotopes; Non-alcoholic Fatty Liver Disease; Nuclear Magnetic Resonance, Biomolecular; Obesity; Obesity, Morbid; Oligopeptides; Oxidation-Reduction; Pancreatic Neoplasms; Particle Size; Particulate Matter; Pepsinogen A; Pesticides; Pharmacogenetics; Phosphatidylinositol 3-Kinases; Phospholipids; Phylogeny; Plasmodium ovale; Plasmodium vivax; Platelet Count; Polyhydroxyalkanoates; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postoperative Complications; Pregnancy; Prevalence; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Domains; Proto-Oncogene Proteins c-akt; Proton Magnetic Resonance Spectroscopy; Pseudogenes; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Rats, Long-Evans; Rats, Sprague-Dawley; RAW 264.7 Cells; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, G-Protein-Coupled; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Repressor Proteins; Resveratrol; Retrospective Studies; Risk Assessment; Risk Factors; RNA, Messenger; RNA, Ribosomal, 16S; Salinity; Salvage Therapy; Seasons; Sequence Analysis, DNA; Seroepidemiologic Studies; Signal Transduction; Skin; Snails; Soluble Guanylyl Cyclase; Solutions; Spain; Species Specificity; Spheroids, Cellular; Splenic Artery; Stomach Neoplasms; Streptococcus pneumoniae; Structure-Activity Relationship; Sulfonamides; Sunlight; Surface Properties; Surgical Instruments; Surgical Wound Infection; Survival Rate; Tetrahydrouridine; Thinness; Thrombocytopenia; Tissue Distribution; Titanium; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Turkey; Ubiquinone; Urologic Neoplasms; Viral Envelope Proteins; Wastewater; Water Pollutants, Chemical; Weather; Wnt Signaling Pathway; Xenograft Model Antitumor Assays; Young Adult | 2007 |
Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Aged; Antioxidants; Dietary Supplements; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Intra-Abdominal Fat; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Overweight; Proton Magnetic Resonance Spectroscopy; Resveratrol | 2018 |
No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease.
Topics: Adult; Body Composition; Glucose Clamp Technique; Humans; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Resveratrol; Triglycerides | 2018 |
Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
Topics: Abdominal Fat; Adult; Aged; Australia; Gastrointestinal Agents; Humans; Insulin Resistance; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Placebos; Resveratrol; Stilbenes; Treatment Outcome | 2014 |
Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
Topics: Adult; Alanine Transaminase; Anthropometry; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cytokines; Diet; Dietary Supplements; Double-Blind Method; Exercise; Fatty Liver; Female; Humans; Inflammation Mediators; Keratin-18; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Polyphenols; Resveratrol; Stilbenes | 2014 |
Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Cytokines; Double-Blind Method; Female; Homeostasis; Humans; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Resveratrol; Stilbenes; Ultrasonography; Young Adult | 2015 |
The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Pressure; Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Fatty Liver; Female; Humans; Insulin Resistance; Lipid Metabolism; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Resveratrol; Risk Factors; Stilbenes; Triglycerides | 2015 |
Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
Topics: Administration, Oral; Adolescent; Dietary Supplements; Double-Blind Method; Female; Humans; Insulin Resistance; Male; Non-alcoholic Fatty Liver Disease; Overweight; Pediatric Obesity; Resveratrol; Stilbenes | 2015 |
Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Double-Blind Method; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Prospective Studies; Resveratrol; Stilbenes | 2016 |
52 other study(ies) available for resveratrol and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Resveratrol reverses the programmed high-susceptibility to non-alcoholic fatty liver disease by targeting the hepatic SIRT1-SREBP1c pathway in prenatal ethanol-exposed rat offspring.
Topics: Animals; Diet, High-Fat; Ethanol; Female; Liver; Non-alcoholic Fatty Liver Disease; Pregnancy; Rats; Resveratrol; Sirtuin 1; Sterol Regulatory Element Binding Protein 1 | 2021 |
Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.
Topics: Antioxidants; Epigenesis, Genetic; Humans; Lipids; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol | 2022 |
Construction of Glycogen-Based Nanoparticles Loaded with Resveratrol for the Alleviation of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease.
Topics: Animals; Diet, High-Fat; Glycogen; Liver; Mice; Nanoparticles; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol | 2022 |
Resveratrol ameliorates nutritional steatohepatitis through the mmu‑miR‑599/PXR pathway.
Topics: Animals; Liver; Mice; Mice, Inbred C57BL; MicroRNAs; Non-alcoholic Fatty Liver Disease; Pregnane X Receptor; Resveratrol | 2022 |
Resveratrol Attenuates High-Fat Diet-Induced Hepatic Lipotoxicity by Upregulating Bmi-1 Expression.
Topics: Animals; Diet, High-Fat; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Reactive Oxygen Species; Resveratrol; Tumor Suppressor Protein p53 | 2022 |
Hepatic-Targeted Nano-enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis.
Topics: Animals; Hepatocytes; Lipids; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Resveratrol | 2023 |
In silico profiling of nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on the treatment of non-alcoholic fatty liver disease.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Capsaicin; Genome-Wide Association Study; Humans; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Polymorphism, Single Nucleotide; Resveratrol | 2023 |
Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; Cholesterol; Diet, High-Fat; Lipoproteins, LDL; Liver X Receptors; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Resveratrol | 2023 |
Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
Topics: Adipokines; Adiposity; Animals; Diet; Diet, High-Fat; Insulin; Insulin-Like Growth Factor I; Lipids; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Rats; Resveratrol; Tumor Necrosis Factor-alpha | 2023 |
Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro.
Topics: Animals; Cholesterol; Diet, High-Fat; Emodin; Hesperidin; Lipid Metabolism; Lipids; Liver; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Resveratrol | 2023 |
Coptidis rhizoma and evodiae fructus against lipid droplet deposition in nonalcoholic fatty liver disease-related liver cancer by AKT.
Topics: Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Evodia; Humans; Lipid Droplets; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt; Quercetin; Resveratrol | 2023 |
Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K/AKT/mTOR and HIF-1/VEGF cascade.
Topics: Animals; Curcumin; Non-alcoholic Fatty Liver Disease; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Resveratrol; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2023 |
Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway.
Topics: Animals; Antioxidants; Decitabine; Diet, High-Fat; Disease Models, Animal; Epigenesis, Genetic; Hep G2 Cells; Humans; Kelch-Like ECH-Associated Protein 1; Lipogenesis; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Random Allocation; Resveratrol; Signal Transduction | 2020 |
Resveratrol Treatment Enhances the Cellular Response to Leptin by Increasing OBRb Content in Palmitate-Induced Steatotic HepG2 Cells.
Topics: Biomarkers; Fatty Acids; Gene Expression Regulation; Hep G2 Cells; Humans; Leptin; Lipid Metabolism; Lipogenesis; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Palmitates; Receptors, Leptin; Resveratrol; Signal Transduction; Sirtuin 1 | 2019 |
SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice.
Topics: Animals; Antioxidants; Apoptosis; Autophagy; Diet, High-Fat; Disease Models, Animal; Enzyme Inhibitors; Hand Strength; Mice; Mice, Inbred C57BL; Muscles; Muscular Atrophy; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol; Sirtuin 1; Tyrosine; Up-Regulation | 2020 |
Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Topics: Animals; Antioxidants; Bacteroides; Body Weight; Clostridiales; Diet, High-Fat; Fatty Liver; Firmicutes; Gastrointestinal Microbiome; Inflammation; Insulin Resistance; Intestinal Mucosa; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Resveratrol | 2020 |
Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription.
Topics: Alanine Transaminase; Animals; Antioxidants; Choline Deficiency; Disease Models, Animal; Hepatocytes; Humans; Interleukin-1beta; Interleukin-6; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; NF-kappa B; Non-alcoholic Fatty Liver Disease; Receptors, Interleukin-1; Resveratrol; Toll-Like Receptors; Transcription, Genetic; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2020 |
Resveratrol Alleviates Endoplasmic Reticulum Stress-Associated Hepatic Steatosis and Injury in Mice Challenged with Tunicamycin.
Topics: Animals; Apoptosis; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Expression Regulation; Hepatitis; Hepatocytes; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol; Sirtuin 1; Triglycerides; Tunicamycin | 2020 |
Topics: Animals; Bile Acids and Salts; Body Weight; Camellia sinensis; Diet, High-Fat; Gene Expression Regulation; Glycine max; Hep G2 Cells; Humans; Isoflavones; Lacticaseibacillus casei; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Polyphenols; Probiotics; Receptors, Cytoplasmic and Nuclear; Resveratrol | 2021 |
Low-dose trans-resveratrol induce poly(ADP)-ribosylation-dependent increase of the PPAR-γ protein expression level in the in vitro model of non-alcoholic fatty liver disease.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Mice; Non-alcoholic Fatty Liver Disease; Poly ADP Ribosylation; PPAR gamma; RAW 264.7 Cells; Resveratrol | 2020 |
Gut Microbiota Induced by Pterostilbene and Resveratrol in High-Fat-High-Fructose Fed Rats: Putative Role in Steatohepatitis Onset.
Topics: Animals; Diet, Carbohydrate Loading; Diet, High-Fat; Dietary Fats; Fructose; Gastrointestinal Microbiome; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Resveratrol; Stilbenes | 2021 |
Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Topics: Acrylamides; AMP-Activated Protein Kinases; Animals; Carbazoles; Cell Line; Cytokines; Diet, High-Fat; Enzyme Inhibitors; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Humans; Liver; Male; Mice; Mice, Inbred C57BL; NAD; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Non-alcoholic Fatty Liver Disease; Oleic Acid; Piperidines; Resveratrol; Signal Transduction; Sirtuin 1; Sterol Regulatory Element Binding Protein 1; Stilbenes | 2017 |
The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells.
Topics: Cell Survival; Cytoprotection; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocytes; Humans; Lipid Metabolism; Mitochondria; Non-alcoholic Fatty Liver Disease; Oleic Acid; Oxidative Stress; Palmitic Acid; Resveratrol; Stilbenes | 2017 |
Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats.
Topics: Animals; Autophagy; Blotting, Western; Body Weight; Caloric Restriction; Diet, High-Fat; Endoplasmic Reticulum Stress; Energy Intake; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Resveratrol; Sirtuin 1; Stilbenes | 2017 |
Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease.
Topics: Animals; Apoptosis; Biomarkers; Combined Modality Therapy; Inflammation; Interleukin-10; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Physical Conditioning, Animal; Rats; Rats, Wistar; Resveratrol; Tumor Necrosis Factor-alpha | 2019 |
Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length.
Topics: Dietary Supplements; Double-Blind Method; Humans; Insulin; Non-alcoholic Fatty Liver Disease; Overweight; Resveratrol | 2018 |
Involvement of autophagy in the beneficial effects of resveratrol in hepatic steatosis treatment. A comparison with energy restriction.
Topics: Animals; Autophagy; Blotting, Western; Caloric Restriction; Diet, High-Fat; Dietary Carbohydrates; Fatty Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Rats, Wistar; Resveratrol; Sucrose | 2018 |
Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Animals, Newborn; Diet, High-Fat; Female; Gene Expression Regulation; Hypolipidemic Agents; Leptin; Lipid Metabolism; Male; Maternal Nutritional Physiological Phenomena; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; Resveratrol; Sirtuin 1; Stilbenes; Weaning | 2018 |
Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy.
Topics: A549 Cells; Animals; Cell Proliferation; Diet, High-Fat; Disease Models, Animal; ErbB Receptors; Hepatectomy; Humans; Liver; Liver Regeneration; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Phosphorylation; Proto-Oncogene Proteins c-akt; Recovery of Function; Resveratrol; Signal Transduction; STAT3 Transcription Factor; Up-Regulation | 2019 |
Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism.
Topics: Activating Transcription Factor 6; Animals; Antioxidants; Diet, High-Fat; Gene Expression Regulation; Hep G2 Cells; Humans; Lipid Droplets; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protein Interaction Maps; Resveratrol; Signal Transduction; Sirtuin 1 | 2018 |
Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
Topics: Animals; Antioxidants; Diet, High-Fat; Hyperuricemia; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Resveratrol; Treatment Outcome | 2019 |
A novel resveratrol-curcumin hybrid, a19, attenuates high fat diet-induced nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Combinations; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Resveratrol | 2019 |
The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression.
Topics: Animals; Diet, High-Fat; Fatty Liver; Gene Expression; Inflammation; Insulin; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Resveratrol; Transcription, Genetic | 2019 |
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Topics: Animals; Body Weight; Cell Membrane; Diacylglycerol O-Acyltransferase; Disease Models, Animal; Down-Regulation; Eating; Enzyme Activation; Glycerol-3-Phosphate O-Acyltransferase; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Liver; Male; Non-alcoholic Fatty Liver Disease; Protein Kinase C; Protein Transport; Rats; Rats, Wistar; Resveratrol; Signal Transduction | 2019 |
Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Topics: Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Hepatocytes; Homeostasis; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; PPAR alpha; Rats; Rats, Sprague-Dawley; Resveratrol | 2020 |
Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system.
Topics: Animals; Antioxidants; Diet, High-Fat; Disease Models, Animal; Endocannabinoids; Gastrointestinal Microbiome; Inflammation; Intestinal Mucosa; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Resveratrol | 2020 |
The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Topics: Animals; Diet, High-Fat; Galactose; Hep G2 Cells; Humans; Liver; Male; Mice, Inbred C57BL; Micelles; Muramidase; Nanoparticles; Non-alcoholic Fatty Liver Disease; Resveratrol; Starch | 2019 |
Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Cell Survival; Enzyme Activation; Fatty Acids, Nonesterified; Gene Expression Regulation; Hepatocytes; Humans; Lipotropic Agents; Male; Methylation; Mice, Inbred ICR; Non-alcoholic Fatty Liver Disease; Phosphorylation; Protein Processing, Post-Translational; Random Allocation; Rats; Resveratrol; Specific Pathogen-Free Organisms; Stilbenes | 2014 |
Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Resveratrol; Stilbenes | 2015 |
Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Gene Expression; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Obesity; Quercetin; Rats, Wistar; Resveratrol; Stilbenes | 2015 |
Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
Topics: Adenylyl Cyclases; Animals; Antioxidants; Autophagy; Cyclic AMP; Dietary Supplements; Enzyme Induction; Enzyme Inhibitors; Fatty Acids, Nonesterified; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Mice, 129 Strain; Microscopy, Electron, Transmission; Non-alcoholic Fatty Liver Disease; Resveratrol; RNA Interference; Second Messenger Systems; Sirtuin 1; Stilbenes | 2015 |
Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats.
Topics: Animals; Diet, High-Fat; Dyslipidemias; Endoplasmic Reticulum Stress; Gene Expression; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Extracts; Rats, Sprague-Dawley; Resveratrol; Stilbenes | 2015 |
Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Topics: Acetylcysteine; Animals; Antioxidants; Biomarkers; Choline Deficiency; Cytoprotection; Disease Models, Animal; Hypolipidemic Agents; Lipids; Liver; Male; Methionine; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats, Wistar; Resveratrol; Stilbenes; Ursodeoxycholic Acid | 2016 |
Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment.
Topics: Animals; Antioxidants; Biological Availability; Disease Models, Animal; Female; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Resveratrol; Stilbenes; Triglycerides | 2016 |
Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Choline Deficiency; Cytokines; Drug Evaluation, Preclinical; Gene Expression; Male; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Resveratrol; Stilbenes | 2015 |
Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.
Topics: Animals; Benzofurans; Cytokines; Diet, High-Fat; Hep G2 Cells; HMGB1 Protein; Humans; Liver; Male; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Protective Agents; Rats; Rats, Sprague-Dawley; Resveratrol; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirtuin 1; Stilbenes; Up-Regulation | 2015 |
Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Disease Models, Animal; Fibrosis; Fluorescent Antibody Technique; Gene Expression; Humans; Immunoblotting; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; Stilbenes; Tumor Necrosis Factor-alpha | 2016 |
Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Energy Metabolism; Fenofibrate; Fructose; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Resveratrol; Stilbenes; Time Factors | 2016 |
Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Humans; Mice; NF-kappa B; Non-alcoholic Fatty Liver Disease; Phosphorylation; Resveratrol; Signal Transduction; Sirtuin 1; Stilbenes | 2016 |
Diet-induced non-alcoholic fatty liver disease affects expression of major cytochrome P450 genes in a mouse model.
Topics: Animals; Cytochrome P-450 Enzyme System; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Isoenzymes; Lipids; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Resveratrol; RNA, Messenger; Stilbenes; Time Factors | 2016 |
Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet.
Topics: Adipose Tissue; Animals; Biomarkers; Blotting, Western; Diet, High-Fat; Dietary Supplements; Disease Models, Animal; Fatty Liver; Ion Channels; Liver; Male; Mitochondrial Proteins; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Real-Time Polymerase Chain Reaction; Resveratrol; RNA, Messenger; RNA, Ribosomal, 18S; Stilbenes; Triglycerides; Uncoupling Protein 2; Up-Regulation | 2012 |
Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.
Topics: Animals; Energy Metabolism; fas Receptor; Fatty Liver; Gene Expression; Lipid Metabolism; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Receptors, LDL; Resveratrol; Scavenger Receptors, Class B; Stilbenes; Thyroid Hormone Receptors beta; Weight Gain | 2013 |